Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Semistructured Patient Interviews Identify Facilitators of MM Treatment Initiation, Continuation
Source: Myeloma - Hematology Advisor Researchers identified 3 factors that encourage patients with MM to initiate and continue their treatment over the long term. Read More
CAR-T Therapy May Help Slow Multiple Myeloma Progression
Source: Myeloma - Hematology Advisor Researchers sought to determine whether CAR-T therapy with cilta-cel would slow progression of multiple myeloma. Read More
Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma
Source: Pharmacy Times articles Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells. Read More
Belamaf Yields Comparable PFS vs Pomalidomide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Source: Myeloma - Hematology Advisor Researchers sought to determine whether belamaf would improve PFS rates compared with Pd among patients with relapsed/refractory multiple myeloma. Read More
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Pharmacoscopy Platform Creates Automated, Personalized Selection of Treatment Options for Patients With Multiple Myeloma
Source: Pharmacy Times articles Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs. Read More
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
Source: Myeloma : nature.com subject feeds Post Content Read More
IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Source: Myeloma : nature.com subject feeds Post Content Read More
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Recent Publications
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e389860. doi: 10.1200/EDBK_389860. ABSTRACT Despite recent advancement of treatment strategies in multiple myeloma (MM), patients with relapsed/refractory MM disease, particularly after triple-class refractoriness, continue to...
Bilateral Exudative Retinal Detachments and Panuveitis in a Patient with Multiple Myeloma
Ocul Immunol Inflamm. 2023 Jun 8:1-6. doi: 10.1080/09273948.2023.2217914. Online ahead of print. ABSTRACT PURPOSE: To report a case of bilateral exudative retinal detachments and panuveitis in a patient with multiple myeloma (MM). CASE REPORT: A 54-year-old patient...
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
Int J Clin Pharm. 2023 Jun 8. doi: 10.1007/s11096-023-01608-7. Online ahead of print. ABSTRACT BACKGROUND: Daratumumab and isatuximab are anti-CD38 monoclonal antibodies indicated for the treatment of multiple myeloma. These agents can increase the risk of infectious...
Starving multiple myeloma cells via CDK7 inhibition
Blood. 2023 Jun 8;141(23):2787-2788. doi: 10.1182/blood.2023020254. NO ABSTRACT PMID:37289477 | DOI:10.1182/blood.2023020254
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma
Br J Haematol. 2023 Jun 7. doi: 10.1111/bjh.18909. Online ahead of print. ABSTRACT Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their...
Severe laryngeal edema after CAR-T cell treatment in a patient with multiple myeloma: A case report
Clin Case Rep. 2023 Jun 5;11(6):e7281. doi: 10.1002/ccr3.7281. eCollection 2023 Jun. ABSTRACT This case aims to report an unusual clinical situation with uncommon and severe side effects, which can even be life threatening for the patient. The ENT and Hematology...
Re-expansion of vertebral compression fractures in patients with multiple myeloma with percutaneous vertebroplasty using spinejack implants: a preliminary and retrospective study
Front Surg. 2023 May 23;10:1121981. doi: 10.3389/fsurg.2023.1121981. eCollection 2023. ABSTRACT OBJECTIVE: To retrospectively evaluate the feasibility and effectiveness of vertebroplasty using Spinejack implantation for the treatment and stabilization of painful...
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis
Leuk Res. 2023 May 23;131:107324. doi: 10.1016/j.leukres.2023.107324. Online ahead of print. ABSTRACT Anti-CD38 monoclonal antibodies (mAbs) are commonly used for treating newly diagnosed and relapsed/refractory (r/r) multiple myeloma (MM). However, concerns have been...
